Literature DB >> 11453898

Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--towards a consensus.

G T Tucker1, J B Houston, S M Huang.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11453898      PMCID： PMC2014497          DOI： 10.1046/j.0306-5251.2001.temp.1441.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  25 in total

1.  A quantitative framework and strategies for management and evaluation of metabolic drug-drug interactions in oncology drug development: new molecular entities as object drugs.

Authors:  Karthik Venkatakrishnan; Michael D Pickard; Lisa L von Moltke
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

Review 2.  Database analyses for the prediction of in vivo drug-drug interactions from in vitro data.

Authors:  Kiyomi Ito; Hayley S Brown; J Brian Houston
Journal:  Br J Clin Pharmacol       Date:  2004-04       Impact factor: 4.335

3.  Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.

Authors:  Eleanor J Guest; Karen Rowland-Yeo; Amin Rostami-Hodjegan; Geoffrey T Tucker; J Brian Houston; Aleksandra Galetin
Journal:  Br J Clin Pharmacol       Date:  2011-01       Impact factor: 4.335

4.  Changes in the defined daily dose; CYP2D6/CYP3A metabolism as an indicator for dose-setting problems.

Authors:  P Stolk; E R Heerdink; H G M Leufkens
Journal:  Eur J Clin Pharmacol       Date:  2005-04-28       Impact factor: 2.953

5.  Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant.

Authors:  Hayley S Brown; Kiyomi Ito; Aleksandra Galetin; J Brian Houston
Journal:  Br J Clin Pharmacol       Date:  2005-11       Impact factor: 4.335

6.  Predictions of the in vivo clearance of drugs from rate of loss using human liver microsomes for phase I and phase II biotransformations.

Authors:  Michael A Mohutsky; Jenny Y Chien; Barbara J Ring; Steven A Wrighton
Journal:  Pharm Res       Date:  2006-03-24       Impact factor: 4.200

7.  Integration of preclinical and clinical data with pharmacokinetic modeling and simulation to evaluate fexofenadine as a probe for hepatobiliary transport function.

Authors:  Brandon Swift; Xianbin Tian; Kim L R Brouwer
Journal:  Pharm Res       Date:  2009-06-04       Impact factor: 4.200

8.  Inhibitory effect of medroxyprogesterone acetate on human liver cytochrome P450 enzymes.

Authors:  Jiang-Wei Zhang; Yong Liu; Wei Li; Da-Cheng Hao; Ling Yang
Journal:  Eur J Clin Pharmacol       Date:  2006-04-28       Impact factor: 2.953

9.  Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase.

Authors:  David J Greenblatt; Diane E Peters; Lauren E Oleson; Jerold S Harmatz; Malcolm W MacNab; Noah Berkowitz; Miguel A Zinny; Michael H Court
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

10.  Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects.

Authors:  Kelvin J Cooper; Paul D Martin; Aaron L Dane; Mike J Warwick; Ali Raza; Dennis W Schneck
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.